RxDoctor Payments Data

Gregory Halperin, MD

Ophthalmology · Bloomington, ILNPI 1760423206

Payments from drug & device makers

$449in general payments, 2019–2025

Across 8 payments — averaging $56.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$203
  • Aerie Pharmaceuticals, Inc.$101
  • Johnson & Johnson Surgical Vision, Inc.$73
  • Glaukos Corporation$29
  • Sight Sciences, Inc.$25
  • Omeros Corporation$19

What the payments were for

  • Food & beverage$449100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$449 in reported general payments places this provider in the 30th percentile of 773 ophthalmology providers in Illinois.

See all ophthalmology providers in Illinois

Medicare billing

Part B allowed, 2024
$518,144
Medicare patients
1,660
Services billed
4,385

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine82$98,907
LumiganBimatoprost111$54,402
Cyclosporine69$27,775
Prednisolone Acetate284$12,926
RocklatanNetarsudil Mesylat/Latanoprost17$11,389
CombiganBrimonidine Tartrate/Timolol23$8,960
Alphagan PBrimonidine Tartrate27$8,299
Latanoprost804$7,080
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol56$6,915
Brimonidine Tartrate120$5,859
Travoprost27$4,684
Timolol Maleate224$3,338
Ketorolac Tromethamine197$3,065
Ofloxacin218$1,893
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat115$1,294

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Aerie Pharmaceuticals, Inc.Rocklatan$101$11,38917 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 773 ophthalmology providers in Illinois.

Other ophthalmology in Bloomington

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →